Sino-Israeli Fund's investment project listed on Swiss Stock Exchange

Swiss biotechnology company BioVersys went public on the Swiss Stock Exchange with the stock code "BIOV" on Feb 7.

The company focuses on developing novel antibacterial drugs for the treatment of life-threatening infections. In its initial public offering (IPO), 2,222,221 new shares were issued at 36 Swiss Francs ($39.45) per share, with a total market value of approximately 216 million Swiss Francs.

BioVersys plans to use the proceeds to advance its flagship product BV100 into Phase III clinical trials, which is intended for treating hospital-acquired infections.

This listing marks BioVersys' transition from a startup to a publicly traded company, elevating Switzerland's position in the global biotechnology innovation landscape.

With the aging population and the improvement of medical standards in China, the demand for new, efficient, and low-resistance antibacterial drugs is increasing. BioVersys has established its Chinese regional headquarters in the Guangzhou International Bioland.

BioVersys CEO Marc Gitzinger (third from the left) and CFO Hernan Levett (second from the left) visit Bioland. [Photo/WeChat account: guangzhougaoxinqu]

The Sino-Israeli Fund under the Guangzhou High-Tech Zone Investment Group has been following the BioVersys project closely and made an investment in September 2024.

The Sino-Israeli Fund, led by Doctor Yehoshua (Shuki) Gleitman, former deputy minister of Industry and Trade of Israel and chief scientist's office director, was established by the High-Tech Zone Group and aims to introduce high-quality international projects to drive innovation in the biopharmaceutical industry.

This listing further validates the investment vision and strength of the Sino-Israeli Fund in the field of biopharmaceuticals.

Share - WeChat